861106-91-4

Usage

Uses

Used in Pharmaceutical Industry:
BENZENEMETHANOL, 2-BROMO-6-NITROis used as an intermediate in the synthesis of pharmaceutical compounds for its ability to be easily modified and functionalized. The presence of the bromo and nitro groups allows for further chemical reactions, making it a versatile building block in the development of new drugs.
Used in Chemical Synthesis:
BENZENEMETHANOL, 2-BROMO-6-NITROis used as a chemical intermediate for the production of various specialty chemicals, including dyes, pigments, and agrochemicals. Its unique functional groups enable it to participate in a range of chemical reactions, facilitating the synthesis of complex molecules.
Used in Research and Development:
BENZENEMETHANOL, 2-BROMO-6-NITROis utilized in research and development settings as a model compound to study the effects of bromine and nitro substitutions on the chemical and physical properties of benzyl alcohol derivatives. This knowledge can be applied to the design and synthesis of new molecules with specific properties and applications.
Used in Fragrance Industry:
Although BENZENEMETHANOL, 2-BROMO-6-NITROmay not be used directly as a fragrance ingredient due to its potential reactivity, it can be used as a precursor in the synthesis of novel fragrance compounds. The unique combination of functional groups allows for the creation of new scents with distinct characteristics.
Used in Analytical Chemistry:
BENZENEMETHANOL, 2-BROMO-6-NITROcan be employed as a reference compound in analytical chemistry for the development and validation of analytical methods. Its distinct chemical properties make it suitable for testing the performance of chromatographic, spectroscopic, and other analytical techniques.

InChI:InChI=1/C7H6BrNO3/c8-6-2-1-3-7(9(11)12)5(6)4-10/h1-3,10H,4H2

Upstream product

• 58579-54-7 3-bromo-2-(bromomethyl)-1-nitrobenzene 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 861106-90-3 2-bromo-6-nitrobenzyl acetate 

Downstream Products

• 861106-92-5 (2-amino-6-bromophenyl)methanol 
• 1147531-02-9 ((2-bromo-6-nitrobenzyl)oxy)(tert-butyl)dimethylsilane 
• 1347720-73-3 C₂₁H₂₄BrN₃O₅ 
• 1418128-56-9 2-[2-(tert-butyl-diphenyl-silanyloxymethyl)-3-nitro-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 1418128-59-2 2-(tert-butyl-diphenyl-silanyloxymethyl)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxborolan-2-yl)-phenylamine 
• 1418128-61-6 4-tert-butyl-N-[(2-tert-butyl-diphenyl-silanyloxymethyl)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-benzamide 
• 1418128-54-7 (2-bromo-6-nitro-benzyloxy)-tert-butyl-diphenyl-silane 
• 1147531-06-3 2-(tert-butyldimethylsilanyloxymethyl)-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenylamine 
• 1147530-03-7 N-[2-(tert-butyldimethylsilanyloxymethyl)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-4-dimethylaminobenzamide 
• 1198765-15-9 2-(3-bromo-2-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)-6-cyclopropyl-3-hydroxy-3,4-dihydro-2H-isoquinolin-1-one 
• 1198765-16-0 2-[3-bromo-2-(tert-butyldimethylsilanyloxymethyl)phenyl]-6-cyclopropyl-2H-isoquinolin-1-one 

Relevant academic research and scientific papers

Novel Bruton's tyrosine kinase inhibitor as well as preparation method and application thereof

The invention relates to a reversible novel Bruton's tyrosine kinase inhibitor which comprises a compound of a formula (I) as shown in the specification, and a stereisomer, a aquo-complex, a solvent compound, a pharmaceutically acceptable salt, an eutectic crystal or a predrug of the compound. The invention further relates to a preparation method of the compound and a method and the application ofthe novel compound in inhibiting BTK (Bruton's Tyrosine Kinase) kinase activity and mutant BTK kinase activity.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF

Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF

At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.

1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATME

The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z is -(CRa/sup